Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Short Interest Down 28.9% in February

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) saw a significant drop in short interest in February. As of February 13th, there was short interest totaling 17,842 shares, a drop of 28.9% from the January 29th total of 25,106 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average trading volume of 79,857 shares, the short-interest ratio is currently 0.2 days. Based on an average trading volume of 79,857 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Hong Kong Pharma Digital Technology presently has an average rating of “Sell”.

Hedge Funds Weigh In On Hong Kong Pharma Digital Technology

An institutional investor recently bought a new position in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. acquired a new stake in shares of Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned approximately 0.39% of Hong Kong Pharma Digital Technology as of its most recent SEC filing.

Hong Kong Pharma Digital Technology Trading Up 1.5%

NASDAQ HKPD opened at $0.66 on Friday. Hong Kong Pharma Digital Technology has a 12 month low of $0.63 and a 12 month high of $2.76. The company’s fifty day moving average price is $0.78 and its two-hundred day moving average price is $1.04.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.